← Eichor
Study identifier: NCT04708288 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

To Evaluate the Safety and Clinical Performance of the ARCHIMEDES Biodegradable Biliary and Pancreatic Stent

Condition: Obstructed Biliary and Pancreatic Duct  ·  Sponsor: QualiMed Innovative Medizinprodukte GmbH

PhaseN/A
Planned participants198
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Significant experience with biodegradable materials has been reported in the orthopedic literature; in particular; biodegradable stents have been used in the endovascular and urologic epithelium. Stents are typically made from polymeric materials including Polylactic Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG), Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g., lactic acid, which is removed from the body by normal metabolic pathways. In the field of gastroenterology, these stents were first introduced in patients with an esophageal stenosis with encouraging results, although esophageal hyperplasia was a frequently encountered complication. For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that demonstrated that the stents were safe and well tolerated. These stents provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary at various times aft…

This description comes directly from the study's public registry record.

Talk to the study team

NIta Gondaliya  ·  +49 1716578285  ·  ngondaliya@q3medical.com

Manfred Guelcher  ·  +4941716578200  ·  mguelcher@q3medical.com

Always discuss trial participation with your own doctor first.

Locations (11)

HUS Helsinki University HospitalHelsinki, FinlandCompleted
Hôpital Européen Georges-Pompidou HEGP Service d'Hépato-gastro-entérologie et endoscopies digestivesParis, FranceActive Not Recruiting
Evangelisches Krankenhaus DüsseldorfDüsseldorf, GermanyRecruiting
Emek Medical CenterAfula, IsraelCompleted
Endoscopy Unit, Humanitas Research HospitalRozzano, Milano, ItalyActive Not Recruiting
AUSL Romagna Ospedale Morgagni - PierantoniForlì, ItalyCompleted
Gastroenterology and Digestive Endoscopy Unit Fondazione I.R.C.C.S. Policlinico San MatteoPavia, ItalyActive Not Recruiting
UCBM - Campus Bio-Medico UniversityRoma, ItalyActive Not Recruiting
Tan Tock Seng Hospital Pte Ltd,Singapore, SingaporeCompleted
University Medical Center LjubljanaLjubljana, SloveniaRecruiting
Hospital Universitario de SalamancaSalamanca, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04708288